We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Plant Impact | PIM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.45 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.45 | 10.45 |
| Top Posts |
|---|
Posted at 01/3/2018 13:05 by mthead1968 Wan, I have been right about the failure of the BoD to address a failing (now failed) strategy. All you have done is encourage investors that all was rosy in the garden. If anyone has been proven wrong, it is most emphatically you. The business has failed, some of us saw it coming and you clearly did not. |
Posted at 28/2/2018 07:32 by wan From Bayer's Full Year Results -February 28, 2018 Fiscal 2017: Bayer: business at prior-year level - on track with strategy Crop Science held back by situation in Brazil Sales in the agriculture business (Crop Science) moved back by 2.2 percent (Fx & portfolio adj.) to 9.577 billion euros. This was mainly due to the situation in the Brazilian crop protection business, where volumes were held back by unexpectedly high inventories in the market. "We have initiated a number of measures to normalize this situation. For example, we took back crop protection products from our distribution partners and concluded new agreements at amended terms," said Baumann. "We are now seeing that these measures are taking effect." hxxps://www.investor If Bayer were able to amend terms for their distributors, one wonders why not in turn for their suppliers? Meanwhile Bayer are still active with regard to marketing Veritas (inc video) - 27/02/2018 Agrodinamica in Deciolandia, Brazil saw over 400 soybean growers visit the Bayer CropScience stand for a 'Jornada Tecnica' to learn more about Veritas yesterday. Breno Araguaia, a Plant Impact Market Development Agronomist was there to share insight with growers. |
Posted at 27/2/2018 09:52 by wan All the documents are available on PI's website under the Investors drop-down bar, "Offer". |
Posted at 27/2/2018 07:56 by wan I note the publication of the Scheme Document (which I have yet to fully read), not that I can see it on PI's website....the clock is ticking on any increased offers coming in and is ticking on the final chapter of PI!'All' the documents are available on the Investor page on Croda's website - The next stage - If 75% of shareholders (at the Court meeting and General meeting or by proxy) approve the scheme, the court will decide at a further hearing whether to sanction the scheme, and will look at whether the approved scheme is fair. If the court sanctions the scheme, the scheme is binding on all affected members, creditors and the company. I also note that Croda reserves the right to elect, subject to receipt of Takeover Offer Consent, to implement the Offer by way of a Takeover Offer for the entire issued and to be issued share capital of Plant Impact as an alternative to the Scheme. I further note news elsewhere today of a placing that values Plant Health Care (PHC), a company in our sector with near identical revenues to PI and no profits yet, at circa £35m! |
Posted at 05/2/2018 08:57 by here and there That is your discussion, not the relevant one to investors. You carry on fella.I am 100% correct in my analysis of this company. It is why the share price is 6p not 60p. Perhaps you should spend more time on information that is more pertinent to making money! |
Posted at 02/1/2018 11:14 by wan Glen...CommunicationOne of my points, which I did intimate at previous to this situation (and due to other constraints and commitments I could not follow it up adequately), was that PI's Research and Development Platform and Pipeline Presentation, initially announced and widely disseminated back in August, appears to indicate that there was already a change occurring in the relationship with Bayer. Whether the need to explore strategic options were borne out of frustration with Bayer (due to Bayer's focus on the Monsanto acquisition) and the arguably pressing need to reduce our exposure to one large player (and potentially getting a lot larger!), or a change in Bayer's strategy (or indeed the greater risk of such), remains to be seen. But clearly the BOD were active, as opposed to torpid or "in some sort of trance with Bayer"! Most investors understandably wanted to see a reduction in the exposure to Bayer and Veritas, and we will now have to wait and see what options come out of potentially moving away from a future (and timescale) that would have been dominated and dictated to by Bayer. Without Plant Impact being acquired, it needed to happen, but it was never going to be an easy task and I believe we are now witnessing that fact! However, the Management have a lot of previous experience in dealing with complex and demanding situations much bigger than this within the agricultural world. Ultimately the BOD are custodians of shareholder value, and selling out for a derisory offer based on a market cap of £6m would hardly be described as providing good shareholder value. And I am confident they are both capable and actively striving to achieve something much better! Currently we have actively interested parties looking at various options, including potentially buying Plant Impact, so it is far too soon to assume we are short of options that will realise better value than where we are today. One assumes that in any regard we will get the option to vote via a General Meeting - Excerpt from the AGM Notice Resolution 10: General Meeting – other than AGM – 14 clear days’ notice The Directors wish to continue to have the flexibility to call General Meetings (other than AGMs) on 14 clear days’ notice. The Directors do not expect to use this power unless urgent action is required on the part of the shareholders. The authority conferred by this resolution will be proposed as a Special resolution, and if passed, the approval and authority given shall expire at the next AGM of the Company or (if earlier) on 15 March 2019, when it is expected that a similar resolution will be proposed. (END) If you hold your shares via a nominee account/broker and you want to vote at meetings, the following link will explain how you can do that - Nominee Accounts ATTENDING AND VOTING AT GENERAL MEETINGS IF YOU ARE IN A NOMINEE ACCOUNT |
Posted at 17/12/2017 12:35 by wan At the AGM I had the pleasure of meeting Non-exec Chris Tyler (briefly), Richard Amos (outgoing CFO) Ib Jenson (incoming CFO, who comes from Syngenta), and I was also able to talk with both our CEO and Chairman after the meeting.I did not count the attendance, but I estimate there were at least 15 people in the meeting, including the BoD. The Bayer issue and related news was covered adequately, so there were only two question from the floor, both were from private investors and with one of the questions coming from me. The question from the other private investor, was whether it was deemed that Bayer were playing tactically in order to pick-off PI on the cheap? That was not the Boards interpretation of the current situation, but acknowledged nonetheless that it was a possibility. My question was regarding Veritas for cotton, which the CEO answered. He confirmed that Veritas for cotton is an identical formulation/product to Veritas for soybeans. The total cotton acreage in Brazil is relative small compared to soybeans. However, Veritas is applied 3 times to cotton, so the volume required per hectare is greater than that for soybeans. The season for cotton extends beyond the soybean season, so obviously this provides for increased use and a new growth opportunity, but for me it was also a strong indication that PI's technologies in soybean (and possibly wheat), can indeed be extended to other major world crops (an aspect which one would assume to be of interest to parties other than Bayer). December 8, 2017 Brazilian Cotton Acreage could increase 20% in 2017/18 From my chat with the CEO and Chairman; Bayer related issues aside, apparently the mood within the company and its employees is very buoyant and optimistic, with Plant Impact being the "busiest they have ever been." Clearly both PI and Bayer expect to shift a reasonable amount of Veritas in Brazil during the current season (4,300 growers purchased Veritas last season), but it was Bayer's people that put the amount of Veritas stock in the channel and the Brazilian backdrop that ultimately caused their inventory issues for both Veritas and indeed the now high stocks of other inputs that are also in Bayer's Brazil channels. In the scheme of things, PI are a tiny consideration for Bayer, especially with their issues as a whole in Brazil (not just Veritas), but even more so with regard to their acquisition of Monsanto, which is not exactly going to plan and subsequently is being pushed further out into 2018. And almost without doubt, Bayer will be required to make further divestment's. We also discussed the significant amount of Private Equity capital currently looking for opportunity in agriculture. The upside to the vast amount of money flowing into PE is that there is strong competition for deals, and as we discussed, subsequently this has made deal making a lot more expensive (higher valuations). Asliomar Bio, who I have referred to previously and who like PI are developing chemical crop enhancement products, very recently raised $12.25m and is apparently valued at over $40m (equivalent to £30m and 32p in PI terms). Asilomar's first product is not expected to be on the market until 2019 or 2020. 12th December 2017 Crop protection attracts big dollar amid PE push earlier in the start-up lifecycle full story - In my opinion and given PI's development pipeline and existing real products/sales, I am hopeful that this healthy backdrop in PE will feed across into making other options available to PI, but hopefully not just from Private Equity! Albaugh is certainly an interesting, ambitious and forward looking company, and hopefully they will make for a successful, refreshing and progressive partner. The PI product that they will be selling is manufactured here in the UK and I look forward to seeing what other PI products they will be selling in due course. Albaugh’s vision is to be the premier supplier of off-patent agricultural products and bring novel technology into three strategic business units Crop Protection, Specialty and Seed Treatment in the US market and around the globe. According to Albaugh's CEO, the resistance of the fungus that causes Asian rust to so-called systemic products will mean that by 2022 at least 80% of Brazilian soybean area, around 100 million hectares, will be treated with multisite fungicides. He also stated that Albaugh was one of the companies that grew the most in the Brazilian market for pesticides - it jumped from 1.5% to 2.4% in share, while the sector had a decline of 1% in sales. The company was expecting to raise its revenues to $ 230 million, up from $ 150 million in 2016 (+ 53%). By 2021, the goal is to reach $ 500 million, which is now equivalent to 25% of the company's global business. Plant Impact have real products, real sales and an extensive product development pipeline, yet their shares can currently be bought at a fraction of the cost compared to the valuations being applied to Asilomar Bio and other related companies that have no products on the market, or less product and less sales. So I am hopeful that at least some realignment/reinstat |
Posted at 14/12/2017 08:17 by cjac39 its poor news badly delivered but :- bayer charged PI a lot of money for distributing - PI know who all end buyers are - the shareholder base is not dominated by any single investor who will torch smaller - the shareholders are rich enough to carry PI through negative burn into cashflow breakeven - in small stocks, time and again, its not mr market but mr market makers who pull the share price down pushing out retail investors who panic sell until some marginal buyers appear - most marginal buyers will wait until it settles before buying reinforcing above BUT - playing this out in public is a poor strategy - cash burn needs arresting with plan for cash neutral to remove blow up risk - previously interested prospective buyers will look at mkt cap as ref price - without comp tension the offered price will be low its up to resolve of existing sh to back company and hold out for fair value upside is therefore gone but its prob worth 10-15p and todays price looks decent risk reward |
Posted at 13/11/2017 23:24 by bigglesbingham Nice post Wan id argue s bit of both. PI discount overblown down to uncertainty Eden is too pricey on optimism. Very fickle investors, a few positive rns's and PI will be quickly recovering , no news - then shareprice will remain suppressed as private investors such as rlivsey sell out. |
Posted at 13/11/2017 14:13 by wan I have been looking for comparisons in regard to what valuation the market put's on PI and their research pipeline/platform, and I would be interested if others have made any comparisons (negative or positive examples).Nothing will be a perfect comparison, but here is just one I had a look at recently; Eden Research is an IP-led technology development and commercialisation company focused on plant protection, animal and human health, and biocides. The Company has a number of patents and a pipeline of products at differing stages of development targeting specific market opportunities. The Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company’s technologies. To date, the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and signing commercial agreements and is now entering the commercial stage of its development. £12m invested in IP & registrations 9 countries have granted product authorisation 5 Current trials on 5 continents Our vision is to be the leader in sustainable bioactive products enabled or enhanced by our novel encapsulation and delivery technologies Product sales have commenced and the company’s commercial pipeline is strong Eden has regulatory clearance for its first product in multiple countries Our initial focus is on protecting high-value crops - improving crop yields and value Our products are based upon natural chemistries but deliver performance, ease of use, and cost on par with conventional pesticides – without residues There is substantial scope for exploitation of the core technologies beyond crop protection Eden's most recent financials - interim results for the six months ended 30 June 2017. Financial highlights · Revenue for the period increased to £1.03m (H1 2016: £0.11m) · Operating Profit for the period increased to £0.21m (H1 2016: loss of £0.86m) · Cash and cash equivalents of £3.66m (H1 2016: £2.01m) · Strategic investment of £2.2m by Sipcam and placing of £0.2m (gross) to institutional investors · Expanding investment in regulatory clearances unlocking commercial potential in new, important territories Business highlights Commercial, Regulatory and IP: · Multiple commercial agreements signed with Sipcam SpA (Sipcam) including an Evaluation and Option Agreement for which a fee of €0.6m (£0.5m) was paid to Eden, establishing a long term collaborative partnership · EU approval of Eden's first agrochemical, fungicide product, 3AEY, gained in France and first commercial sales achieved · Further EU approvals received in Cyprus, Albania and Portugal (post period end) · Label extensions received in Kenya now include authorisation for the treatment of roses · Extension of 3AEY patent protection in Spain, Greece and Cyprus and nematicide patent granted in US · New terms agreed with University of Massachusetts Medical School ("UMMS") for licence to next-generation technology Eden's market cap is circa £20m on half year revenues of £1m. Pi has a similar market cap of circa £20m PI's most recent financials - Highlights from preliminary results for the year ended 31 July 2017. · Revenue increased 17% to £8.5m (2016: £7.2m), primarily reflecting Veritas® sales in Brazil - Reported revenue growth reflects the strength of the US Dollar - constant currency revenue growth was 2% - First sales of Veritas®/Fortali - Veritas® purchase plan agreed for 2017/18 Brazil growing season based on our commercial partner's end-user sales targets - Increased sales of Banzai™ cocoa product · Gross profit increased 19% to £6.7m (2016: £5.6m) · Total R&D investment increased 43% to £4.2m (2016: £2.9m), including £1.6m of capitalised costs (2016: £1.2m) with novel new compounds identified and pipeline progress achieved · R&D pipeline summary issued in August 2017 to give greater visibility to investors and industry partners of our progress in R&D - Complete season-long portfolio of soybean products being tested over 2017/18 Brazil growing season - Discovery phase activities increased with expanded molecule discovery capability yielding new compounds - new academic partnerships announced - Early indications of product extension potential beyond current target crops · Sales and marketing costs increased to £5.3m (2016: £2.9m) with expansion of commercial activities in the USA and Argentina and additional marketing investment in Brazil and West Africa. · Cash at 31 July 2017 of £7.2m (31 July 2016: £5.6m), reflecting a successful placing announced on 26 July 2017 to raise £4.0m before expenses The market applies a similar market cap to PI for full year revenues of £8.5m and forecast revenues of circa £13m. Eden has made a very small profit at the half year of £200k on sales of £1m and presumably there will be a subsequent and continuing increase for the full year. Arguably PI are far more advanced commercially. Obviously we are not able to compare the pipelines, and obviously it's not a perfect comparison, but again and in my opinion, PI are more advanced. Whether this demonstrates in any way that there might be too much of discount being applied to PI (rather than too high a price for Eden) is up to the reader to analyse further and decide. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
